Argus Downgrades Regeneron Pharma (REGN) to Hold
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $618.95 +2.66%
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Argus analyst Jasper Hellweg downgraded Regeneron Pharma (NASDAQ: REGN) from Buy to Hold.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $521.00 yesterday.
You May Also Be Interested In
- Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG
- Oppenheimer Downgrades AT&T (T) to Perform, 'Broadband Subscribers Are at Risk from Satellite Competition'
- WHO recommends Regeneron antibody for Bundibugyo Ebola outbreak
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
